Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDEA trial for delayed nausea and vomiting prevention after moderately emetogenic chemotherapy
NL-OMON44716Phase 3Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexamethasone, metoclopramide and palonosetron in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Vrije University Medical Center. Primary endpoints: Primary efficacy endpoint, Primary tolerability endpoint and 1 more. Started Jul 2013; status: active, not recruiting.
02
Drugs
dexamethasonemetoclopramidepalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NL-OMON44716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44716.